Melatonin attenuates acute renal failure and oxidative stress induced by mercuric chloride in rats

MAYERLY NAVA,1 FREDDY ROMERO,2 YASMIR QUIROZ, Gustavo Parra, Lizette Bonet, and Bernardo Rodríguez-Iturbe.

Melatonin attenuates acute renal failure and oxidative stress induced by mercuric chloride in rats. Am J Physiol Renal Physiol 279: F910–F918, 2000.—We evaluated the effect of melatonin (Mel), a potent scavenger of reactive oxygen species, in the course of HgCl2-induced acute renal failure. Rats received by gastric gavage 1 mg/kg of Mel (n = 21) or vehicle (n = 21), 30 min before the subcutaneous injection of HgCl2 (2.5 mg/kg). Rats were killed at 24, 48, and 72 h, and plasma creatinine (S\textsubscript{cr}), renal histology, proliferative activity, apoptosis, and superoxide-producing cells were studied. We also determined the renal content of malondialdehyde (MDA) and glutathione (GSH) and the activities of glutathione peroxidase and catalase. Mel pretreatment (Mel plasma levels of 3.40 ± 3.15 μg/ml at the time of HgCl2 injection) prevented the increment in S\textsubscript{cr} and reduced tubular necrosis from 41.0 ± 10.5 to 4.2 ± 5.1% of proximal tubules (P < 0.01). Apoptosis and postnecrotic proliferative activity were twice more intense in the group untreated with Mel. Increment in renal content of MDA and decrease in GSH resulting from HgCl2 toxicity were prevented by Mel. Mel also induced an important reduction in superoxide-positive cells. In contrast to the beneficial effects of pretreatment with Mel, the administration of Mel in conjunction with HgCl2 had no effect on the oxidative damage and did not prevent nephrotoxicity. We conclude that the beneficial effects of pharmacological doses of Mel are due to its antioxidant properties.

Nephrotic acute renal failure

Reactive oxygen species (ROS) have been increasingly implicated as mediators of damage in ischemic, toxic, and immune-mediated tissue injuries (23, 26, 57). In HgCl2-induced nephrotoxicity, the reduction in renal content of antioxidants such as glutathione (GSH), as well as the decrease of thiol groups, has been advanced as evidence of the role of ROS in this pathology (21, 22). Furthermore, morphological and biochemical studies have shown that HgCl2 toxicity is associated with a substantial loss of ATP-generating mitochondrial inner membrane surfaces and important loss of activity of the free radical scavenger systems, such as superoxide dismutase and glutathione peroxidase (GSH-Px) (58). However, the evidence for the pathogenic role of oxidant stress in this condition is conflicting. Some (4, 24, 33, 60), but not all (2, 38), studies have demonstrated increased peroxide formation in the kidney and, in addition, the administration of several antioxidants has failed to provide a consistent beneficial effect in this condition (18, 36).

Melatonin (Mel) is the chief secretory product of the pineal gland and has a very potent antioxidant activity, depending mainly on its capacity to act as electron donor (51, 41). In vivo and in vitro, Mel has been found to protect tissues against oxidative damage generated by a variety of toxic agents (reviewed in 7) and metabolic processes, including chemotherapy-induced toxicity (32) and ischemia-reperfusion injury in stomach, liver, and brain (13, 19, 29, 48). More pertinent, Mel has recently been found to protect against adriamycin-induced nephrotoxicity (35). Mel is widely available, relatively free of side effects, rapidly active after oral administration, and commonly used in humans in the treatment of insomnia (8). Therefore, we decided to investigate the effect of Mel in the course of nephrotoxic acute renal failure induced by HgCl2. Our results indicate that pretreatment with Mel improves dramatically the histological and functional damage and the lipid peroxidation in this experimental model.

Mercuric chloride (HgCl₂) has been widely used to study the pathophysiology of nephrotic acute renal failure. Hemodynamic changes, functional alterations, and histological damage in this experimental model are well characterized (16, 50, 55) and include activation of the renin-angiotensin system, profound renal vasoconstriction, reduction in glomerular filtration rate, and progressive azotemia. The renal damage is particularly severe in the proximal tubule. Treatment strategies have been mostly directed to correct the hemodynamic disturbances or the toxic effects of the metal (14, 17, 39, 52, 54).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
MATERIAL AND METHODS

Experimental Design

Studies were done in male Sprague-Dawley rats, weighing 200–250 g and fed on a standard rat chow and ad libitum water ingestion. HgCl₂ (2.5 mg/kg body wt in 0.5 ml 0.9% saline solution) was administered subcutaneously to each one of two groups of rats: 1) HgCl₂-Mel group, consisting of 21 rats that received Mel (1 mg/kg) by gastric gavage, 30 min before injection and 2) HgCl₂ group, consisting of 21 rats that received vehicle (saline solution) instead of Mel by gastric gavage. An additional group of 15 rats received 0.5 ml of 0.9% saline subcutaneously (instead of HgCl₂) and served as a control group. Five to seven rats from each group were killed 24, 48, and 72 h after HgCl₂ by aortic desanguination under ether anesthesia. The kidneys were perfused with iced 0.9% saline solution, removed, and used for histological and biochemical studies.

Plasma levels of Mel were determined in five rats at 30 min (corresponding to the time of HgCl₂ injection), 2 h, and 5 h after administration. Plasma creatinine (S_cr) was determined daily by autoanalyzer methodology. In a separate set of studies, designed to evaluate the effects of Mel administered after HgCl₂, rats were given the same dose of Mel at the same time as the injection of the nephrotoxic agent (n = 5).

Histological Studies

Coronal sections of one kidney were snap-frozen in dry ice and acetone as well as fixed in 15% Formalin and embedded in Paraplast Plus (Monocent, Sherwood Medical Scientific Division, St. Louis MO). Sections (3 µm) were stained with hematoxylin and eosin, Masson's trichrome stain, and periodic acid/Schiff reagent.

Identification of proliferating cells. As described previously (49), 4-µm frozen sections fixed in 4% paraformaldehyde were used in the study of proliferating cell nuclear antigen (PCNA) by the avidin-biotin-peroxidase technique. Briefly, sections were postfixed in 100 and 95% ethanol, incubated for 10 min in 3% H₂O₂, washed with PBS, and incubated with avidin (2 µg/ml Sigma, St. Louis MO) for 20 min, and after being washed with PBS, incubated with 0.001% biotin solution (Sigma) for 20 min. Afterward, sections were incubated for 90 min with monoclonal anti-PCNA antibody (Zymed Laboratories, San Francisco, CA) diluted 1:20 in Tris-buffered saline (TBS), pH 7.8. Subsequently, the sections were incubated with 2.5% low-fat milk solution in TBS for 15 min and then treated with biotinylated F(ab')₂ rat anti-mouse IgG antibody (Organon Teknika, Cappel, Durham, NC) at a dilution of 1:20 in TBS for 1 h. Finally, sections were washed in TBS and incubated with peroxidase-conjugated extravidin (Sigma) for 35 min. The reaction product was exposed by using 0.005% H₂O₂ containing 0.02% 3,3′-diaminobenzidine (DAB) in 50 mmol/l Tris (pH 7.6).

Identification of apoptosis. As described previously (49), frozen sections (4 µm) were fixed in 10% neutral-buffered Formalin and postfixed in ethanol-acetic acid for 5 min at −20°C. Fragmented DNA was terminal deoxynucleotidyl transferase (Tdt)-mediated UTP-biotin nick-end labeled (TUNEL) by using an Apoptag in situ apoptosis detection kit (Oncor, Gaithersburg, MD). Embryonic rat forelimb bud tissue was used as a positive control. Negative controls were renal and forelimb bud tissues incubated with distilled water instead of the TdT enzyme in the reaction buffer. Slides were mounted with SlowFade (Molecular Probes) to delay fluorescence quenching.

Evaluation of histological findings. At least five sections of each biopsy were used for evaluation of PCNA-positive cells, TUNEL-positive cells, and severity of toxic damage by using a microscope (Axioskop, Zeiss; with epifluorescence device) with an ocular piece fitted with a grid. The number of PCNA- and TUNEL-positive cells per cubic millimeter in tubulointerstitial areas was counted as described previously (49). The extension of tubular injury was evaluated in terms of the percent area of the sections showing a given level of histological damage. The severity of the tubular lesions was classified according to the following criteria: no injury = intact tubules with normal tubular cells and preserved brush border; tubular cell damage = loss of the brush border, cytoplasmic extrusion into the lumen, and intraluminal cellular debris; focal tubular necrosis = patchy necrosis of tubular epithelial cells with intraluminal debris and preservation of the tubular basement membrane; and complete tubular necrosis = disruption of the tubular basement membrane and necrosis of the tubule.

Superoxide staining. Superoxide production in renal cells was studied in cryostat sections by the cytochemical method of Briggs et al. (7). Slides were incubated for 60 min at 37°C in the following staining solution: 50 ml 0.05 M Tris-HCl buffer, 1 ml DAB stock solution (5g DAB/132 ml Tris buffer, 0.05 M, pH 7.6), 250 µl 8% NiCl, 32.5 µl 10% NaN₃, and 50 µl 0.5 M MnCl₂. Sections were fixed with 10% Formalin for 10 min and counterstained with 1% methyl green.

Determination of Lipid Peroxidation

Malondialdehyde (MDA) in renal tissue was analyzed by the method of Ohkawa et al. (37). Sections of kidney obtained after cold perfusion as outlined earlier were placed in a total volume of cold 3 ml 100 mM KCl plus 0.003 M EDTA and homogenized. Homogenates were centrifuged at 600 g for 15 min. Four hundred microliters of supernatant were added to 0.2 ml 8.1% SDS, 1.5 ml 20% acetic acid (pH 3.5), 1.5 ml 0.8% thiobarbituric acid, and 0.6 ml water. This solution was heated to 95°C for 60 min. After addition of 1.0 ml water and 5.0 ml of n-butanol-pyridine mixture (15:1, vol/vol), the mixture was vigorously shaken and centrifuged at 2,000 g for 15 min. The absorbance of the upper layer was read at 532 nm (Shimatsu model UV21100S spectrophotometer, Kyoto, Japan). MDA bis-dimethyl acetal (Sigma) was used as the external standard. Results are expressed as nanomoles MDA per milligram protein. The intra-assay variability was deter-
Determination of Kidney GSH

Renal GSH content was measured by a modification of the method of Beutler et al. (6). Renal tissue slices obtained after cold perfusion were suspended in 100 mM KCl plus 0.003 M EDTA and homogenized as described for the determination of MDA above. The homogenates were centrifuged at 600 g for 10 min, and the supernatants were added to 1.5 ml methanolic acid, and particulate debris was removed by centrifugation at 3,000 g for 10 min. Reduced GSH was measured by adding 500 µl of supernatant to 2.0 ml of 0.2 M phosphate buffer and 0.25 ml 0.04% 5,5'-dithiobis-2-nitrobenzoic acid. Absorbance was read at 410 nm. GSH (Sigma) was used as the external standard. GSH content was expressed as nanomoles of GSH per milligram homogenate protein. The intra-assay variability was determined in five sets of triplicate samples (0.82 ± 0.38%).

Determination of Kidney GSH-Px

Renal GSH-Px activity was measured by the method of Lawrence and Burk (30). The reaction mixture consisted of 50 mM potassium phosphate buffer: (in mM) 1 EDTA, 1 NaNO₃, 0.2 NADPH, 1 GSH, and 0.25 mM H₂O₂, as well as 1 U/ml GSSG reductase, pH 7, in a total volume of 1 ml. Enzyme source (0.1 ml) was added to 0.8 ml of the above mixture and allowed to incubate for 5 min at room temperature, before initiation of the reaction by the addition of 0.1 ml peroxide solution. Absorbance at 340 nm was recorded for 2 min, and the activity was calculated using the extinction coefficient of NADPH at 340 nm, 6.22 mM/cm. The result was expressed as nmoles NADPH oxidized per minute per mg of protein. Intra-assay variability was 4.32 ± 2.0%.

Determination of Kidney Catalase Activity

Catalase activity was determined following the method of Aebi (3). Slices of renal tissue obtained as before were transferred to tubes containing 50 mM potassium phosphate, pH 7.0, and homogenized. The homogenates were centrifuged at 600 g for 10 min. Twenty-five microliters of the supernatant were added to 725 µl of a mixture containing 7.7 mM H₂O₂ in 10 mM phosphate buffer, pH 7.0. The change in absorbance was read at 240 nm. The rate constant of a first-order reaction (k) was used: \( k = (1/\Delta t) \times \ln (A1/A2) \), where \( \Delta t \) is a measured interval (30 s) and A1 and A2 are the absorbances at initial and final measurement times, respectively. Catalase activity was expressed as \( k \) per milligram homogenate protein. Intra-assay variability was 4.89 ± 2.63%.

Determination of Mel Levels

Mel levels in plasma were determined by RIA with commercially available kits (Alpco Melatonin RIA, RK-Mel). The Mel extraction from samples was made with reverse-phase extraction columns provided in the kit. The sample application volume was reduced (0.125–0.750 ml instead of 1 ml). The extracts were reconstituted with RIA buffer. Because the plasma Mel levels after oral ingestion of Mel fell in the micrograms per milliliter range, the samples were diluted 162–408 or 1,786–4,88 times. Sensitivity of the method is 0.3 pg/ml. The intra-assay variability of the column extraction and RIA combined was 7.8 ± 1.4%.

Statistical Analysis

Statistical analysis was done with the help of a commercial statistical package (Instat GraphPad) using nonparametric methods (Kruskall-Wallis or Mann-Whitney tests for differences between groups and Friedman tests for serial changes), followed by Dunn's posttests when \( P < 0.05 \). Results are expressed as means ± SD.

RESULTS

Figure 1 shows the serial changes in \( S_{cr} \) concentration in the experimental and control groups. Rats in the HgCl₂ group had an increase in \( S_{cr} \) that reached a peak 48 h after the administration of the toxic agent (309.4 ± 56.5 μmol/l). In contrast, the rats given Mel (HgCl₂-Mel group) had significantly lower levels (100.1 ± 20.3 μmol/l, \( P < 0.001 \)). Plasma Mel levels are shown in Fig. 2. The baseline Mel levels before the studies were 79.4 ± 30.45 μg/ml. After ingestion of 1 mg/kg of Mel, pharmacological levels in the microgram range are obtained rapidly, peak at ~2 h, and remain high for 24 h. Cellular and focal tubular necrosis area examined was significantly lower in the Mel group (29.4% vs. 8.5%) at 48 h. In the Mel group, complete tubular necrosis area examined was also significantly lower (30.5% vs. 6.9%) at 48 h. No significant difference was seen in No injury area examined at any time point. Renal histology of tubular injury is expressed as the area percentage of tubular injury. Statistical significance vs. HgCl₂ group: *\( P < 0.05 \), †\( P < 0.01 \).

### Table 1. Histological findings in proximal tubular cells

<table>
<thead>
<tr>
<th>Time</th>
<th>HgCl₂</th>
<th>HgCl₂ + Mel</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No injury, %</td>
<td>10.1 ± 8.5</td>
<td>28.6 ± 19.4</td>
</tr>
<tr>
<td>Cellular damage, %</td>
<td>29.4 ± 8.3</td>
<td>38.4 ± 14.2</td>
</tr>
<tr>
<td>Focal necrosis, %</td>
<td>30.5 ± 4.9</td>
<td>27.8 ± 11.1</td>
</tr>
<tr>
<td>Complete tubular necrosis, %</td>
<td>25.6 ± 17.2</td>
<td>0 ± 0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>HgCl₂</th>
<th>HgCl₂ + Mel</th>
</tr>
</thead>
<tbody>
<tr>
<td>48 h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No injury, %</td>
<td>2.1 ± 4.3</td>
<td>26.6 ± 9.4†</td>
</tr>
<tr>
<td>Cellular damage, %</td>
<td>21.4 ± 7.9</td>
<td>39.5 ± 9.9†</td>
</tr>
<tr>
<td>Focal necrosis, %</td>
<td>46.6 ± 7.4</td>
<td>24.9 ± 11.6†</td>
</tr>
<tr>
<td>Complete tubular necrosis, %</td>
<td>41.0 ± 10.5</td>
<td>4.2 ± 5.1†</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>HgCl₂</th>
<th>HgCl₂ + Mel</th>
</tr>
</thead>
<tbody>
<tr>
<td>72 h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No injury, %</td>
<td>15.5 ± 18.2</td>
<td>54.2 ± 14.0†</td>
</tr>
<tr>
<td>Cellular damage, %</td>
<td>26.2 ± 18.3</td>
<td>27.7 ± 12.5</td>
</tr>
<tr>
<td>Focal necrosis, %</td>
<td>45.6 ± 11.4</td>
<td>11.3 ± 10.7†</td>
</tr>
<tr>
<td>Complete tubular necrosis, %</td>
<td>36.2 ± 4.3</td>
<td>6.9 ± 6.89†</td>
</tr>
</tbody>
</table>

Values are means ± SD; \( n = 5-7 \) biopsies/group at each time point. Renal histology of tubular injury is expressed as the area percentage of tubular injury. Statistical significance vs. HgCl₂ group: *\( P < 0.05 \), †\( P < 0.01 \).
in that range for at least 5 h. As shown in Fig. 2, at the time when HgCl₂ is injected (30 min after oral administration of Mel) the Mel levels are already 3.40 ± 3.15 μg/ml.

The histological observations are shown in Table 1. Toxic damage in the untreated rats was more intense on day 2, when 41 ± 10.5% of the tubules were completely necrotic (Fig. 3A). Diffuse tubular necrosis was still present in more than one-third of the tubules on day 3. In contrast, the extension of completely necrotic tubules was reduced nine times in the rats treated with Mel at the same time intervals (Table 1 and Fig. 3B).

Proliferating cells in the tubulointerstitial areas were observed from the first day in both experimental groups and increased importantly 48 and 72 h after the nephrotoxic insult. In the HgCl₂ group, the number of PCNA-positive cells increased 20 times during this period, a proliferative reaction twice more intense than in the HgCl₂-Mel group (P < 0.01, Fig. 4). The concomitant apoptosis is shown in Fig. 5, demonstrating that TUNEL-positive cells were present since the first day and increased to a maximal value on day 3. Apoptosis was also significantly higher in the untreated group than in the Mel on days 1, 2, and 3 after HgCl₂ administration (Fig. 5). Figure 6 shows the histological findings of proliferating (A and B) and apoptotic cells (C and D).

In control (vehicle-treated) rats, superoxide-producing cells were very rare (0.43 ± 0.01 superoxide-positive cells/100 tubulointerstitial cells). In the HgCl₂ group, the first day after mercury administration there were 10.3 ± 3.2 superoxide-positive cells/100 tubulointerstitial cells, and increased numbers remained 48 and 72 h later. Mel treatment reduced the number of superoxide-positive cells to control levels (Fig. 7). Representative microphotographs are shown in Fig. 8, A and B.

Figure 9 shows the renal content of MDA. In the HgCl₂ group, MDA doubled on day 1 after HgCl₂ injection (0.47 ± 0.05 nmol/mg protein, P < 0.01). Rats treated with Mel had lower MDA content (P < 0.05 vs. the HgCl₂ group). As shown in Fig. 10, GSH content of the kidney in the HgCl₂ group decreased the first day and returned to control levels at day 3. The fall in GSH

![Fig. 3. Histology in renal biopsies obtained 48 h after HgCl₂ injection. A: severe damage characterized by areas of complete proximal tubular necrosis with disruption of the tubular basement membrane in a rat not treated with melatonin. B: a milder lesion observed in a rat pretreated with melatonin (areas of focal tubular necrosis and tubular cell damage are present). Periodic acid/Schiff staining. Magnification: ×400.](http://ajprenal.physiology.org/)

![Fig. 4. Proliferating cells (proliferating cell nuclear antigen (PCNA)-positive cells/mm²) in acute renal failure induced by subcutaneous injection of 2.5 mg of HgCl₂ in rats that received 30 min before melatonin (hatched bars) or vehicle (filled bars). Error signs are SD. **P < 0.01 vs. the corresponding paired bar.](http://ajprenal.physiology.org/)

![Fig. 5. Apoptosis detected by the terminal deoxynucleotidyl transferase (TdT)-mediated UTP-biotin nick-end labeling (TUNEL) technique (TUNEL-positive cells/mm² in tubulointerstitial areas) in rats receiving HgCl₂ and melatonin (hatched bars) or vehicle (filled bars). Error signs are SD. *P < 0.05, **P < 0.01 vs. the corresponding paired bar.](http://ajprenal.physiology.org/)
content was less marked (3.25 ± 0.2 nmol/mg protein) and less prolonged (normal values of 7.46 ± 2.77 2 nmol/mg protein at day 2) in the group that received Mel (Fig. 10). GSH-Px activity was reduced significantly (P < 0.01) the first day after HgCl2 in the HgCl2 group (65.3 ± 8.4) and in the HgCl2-Mel group (74.8 ± 14.2) in relation to control (100.5 ± 16.6 nmol NADPH oxidized·min⁻¹·mg protein⁻¹). The difference between the experimental groups was not significantly different.

Day 3 studies showed that GSH-Px activity had partially recovered in both experimental groups (HgCl2-Mel = 82.7 ± 12, P > 0.05 vs. control; HgCl2 group = 72.5 ± 16.7 nmol NADPH oxidized·min⁻¹·mg protein⁻¹, P < 0.01 vs. control).

Figure 11 shows the renal catalase activity: Mel treatment induced an increment in catalase activity that was more pronounced at day 1 (0.64 ± 0.04 k/mg protein, P < 0.01 vs. HgCl2 and control groups). After the second day, catalase activity was comparable in the experimental groups.

Administration of Mel at the Same Time of HgCl2

The administration of 1 mg/kg body weight of melatonin at the same time of HgCl2 failed to protect against the toxic effects of the metal. Studies done in five rats showed that Scr levels at 24 h were 238.7 ± 79.7 µmol/l, similar to the levels found when HgCl2 was administered alone (see Fig. 1).

Histological findings were as follows. 1) At 24 h, no injury = 8.5 ± 4.08%, cellular damage = 20.0 ± 7.4%, focal necrosis = 46.3 ± 14.4%, and complete necrosis = 27.3 ± 11.5%. 2) At 48 h, no injury = 0%, cellular damage = 7.0 ± 6.1%, focal necrosis = 53.0 ± 7.9%, and complete necrosis = 39.9 ± 10.1%. 3) At 72 h, no injury = 1.1 ± 1.6%, cellular damage = 19.2 ± 8.3%, focal necrosis = 59.2 ± 12.2%, and complete necrosis = 20.6 ± 5.5%. There are no significant differences between these histological findings and the findings present in the group that received only HgCl2 (shown in Table 1).

Twenty-four hours after the administration of the toxic agent in conjunction with Mel, the renal content of MDA (0.42 ± 0.09 nmol/mg protein), GSH (2.08 ± 0.91 nmol/mg protein), and activities of GSH-Px (62.2 ± 5.0 nmol·min⁻¹·mg of protein⁻¹) and catalase (0.33 ± 0.05 k/mg protein) were not different from the values obtained when HgCl2 was administered alone.
DISCUSSION

The experimental model of acute renal failure induced by HgCl₂ is characterized by intense vasoconstriction, decrease in glomerular filtration rate, tubular collapse, and marked structural and functional tubular abnormalities. Treatment strategies directed to prevent or improve the renal hemodynamic conditions in this experimental model have met with variable degrees of success: among them are suppression of the renin-angiotensin system (14, 16), increase in the urine flow (52), administration of vasodilating prostaglandins (39), inhibition of thromboxane synthesis (54), and administration of a nonspecific hemorrhologic agent, pentoxifylline (53). Other investigations have focused on the use of sulfhydryl-reducing agents and found that treatment of dithiothreitol improved the course of mercury-induced acute renal failure by a combination of metal chelation or sulfhydryl group regeneration (28).

The participation of oxidative stress in the nephrotoxicity associated with HgCl₂ was suggested initially by studies that showed that HgCl₂ administration reduced renal GSH content and depletion of GSH with diethylmaleate resulted in increased severity of HgCl₂-induced acute renal failure (21, 22). Nevertheless, the role of oxidant-dependent injury is controversial because significant renal damage is present before GSH content is depleted (22) and improvement in nephrotoxicity may occur despite reduction in GSH content (9). Furthermore, lipid peroxide formation may (20, 33) or may not (22) be increased. The most convincing evidence for the role of oxidant injury in this experimental model of renal failure was provided by the studies of Nath et al. (36), who showed that, both in vitro and in vivo, HgCl₂ exposure generated massive amounts of hydrogen peroxide that were quenched by pyruvate and both pyruvate and catalase attenuated mercury-induced cytotoxicity.

Treatment with antioxidants has failed to provide definite evidence for or against a pathogenetic role for ROS in HgCl₂ acute renal failure. Intravenous administration of superoxide dismutase and allopurinol, which scavenges and inhibits the production of superoxide radicals, respectively, failed to protect against oxidant injury in this experimental model of renal failure. In contrast, melatonin, an endogenous antioxidant with potential neuroprotective properties, has been shown to have beneficial effects in experimental models of renal failure. In a recent study, melatonin administration was associated with increased renal GSH content and reduced production of lipid peroxides, suggesting a protective role against oxidant injury.
mercuric nephrotoxicity (38). Equally ineffective have been hydroxyl radical scavengers triptophan, N-acetyl tryptophan, and ascorbic acid, but, in contrast, dimethylthiourea and dimethyl sulfoxide, both hydroxyl radical scavengers, were beneficial (38). Dietary manipulations aiming for antioxidant effects have also been inconclusive. Andersen et al. (4) reported that vitamin E protected against mercury-induced lipid peroxidation in the liver, but the effects on the kidney were minor. However, diets deficient in selenium and vitamin E aggravate the renal failure induced by HgCl₂ (36). Zinc administration increases the renal concentration of protective antioxidant enzymes and reduces lipid peroxidation that follows mercury nephrotoxicity (18).

Given the lack of unanimity with regard to the role of ROS-mediated injury in HgCl₂-induced acute renal failure, we decided to test the effect of Mel in this experimental model. Mel (N-acetyl-5-methoxytryptamine) is naturally produced by the pineal gland from serotonin by a process catalyzed by two enzymes: arylalkylamine N-acetyltransferase and hydroxyindole-O-methyltransferase. The synthesis and release of Mel in normal conditions is stimulated by darkness and inhibited by light in response to signals originating in the suprachiasmatic nucleus (44). Circulating Mel is rapidly metabolized, conjugated with sulfuric or glucoronic acid, and excreted in the urine.

Large doses of Mel, resulting in blood levels 10,000 times higher than the physiological time peak, have been given without serious side effects (8). Of the several clinical indications proposed for Mel, the best recognized and supported by placebo-controlled trials is the hypnotic effect, but it has been well documented that the drug is a very potent scavenger of hydroxyl and peroxyl radicals. Mel antioxidant properties result mainly from electron donation, and its unrestricted and peroxyl radicals. Mel antioxidant properties result mainly from electron donation, and its unrestricted

Fig. 11. Renal content of catalase in rats receiving HgCl₂ and melatonin (hatched bars) or vehicle (filled bars). Open bar, control group. Error bars are SD. *P < 0.01 vs. the corresponding paired bar.

ous Mel is less than 6 min (27), but the bioavailability of orally administered Mel is variable. Pertinent to this work, oral doses of 1 mg/kg body weight, similar to those used in this investigation, result in serum Mel concentrations that range from 350 to 10,000 times higher than the physiological peak levels 1–2 h after administration and remain stable for 90 min (56). In the rats from the HgCl₂-Mel group, we also found a large variability, but in all cases very high plasma Mel levels 30 min after administration, coinciding with the injection of mercury, that reached peak concentrations after 2 h. Five hours after the administration by gastric gavage, the plasma Mel levels had dropped to ~13% of the maximal values, but they were still elevated. All these values represent pharmacological concentrations because peak nighttime values in the adult rat are 200-300 µg/ml (25). The baseline levels in our rats, before the administration of Mel, between 8 and 9 Am, were 79.4 ± 30.45 µg/ml, not too different from the values reported by others (25).

The present work documents that pretreatment with Mel offers an important protection from HgCl₂-induced acute renal failure. The increment of S_{\text{cr}} observed with HgCl₂ was markedly ameliorated in the HgCl₂-Mel group (Fig. 1).

Histological damage was markedly improved by Mel treatment (Table 1 and Fig. 3). As reported by others (55), the intensity of the histological damage was more marked 48 and 72 h after the administration of the toxic agent. At these times, the protection offered by pretreatment with Mel is particularly dramatic (Table 1).

Apoptosis and proliferative reaction are also reduced by Mel (Fig. 6). Apoptosis and the proliferative response were present the first day and were maximal at 72 h, when the last group of rats was killed (Figs. 4 and 5). Similar results were reported by Verstrepen et al. (55), who also found a proliferative response the first day and maximal proliferation 4 days after HgCl₂ administration. To our knowledge, there are no serial studies on the apoptosis induced by HgCl₂. However, apoptosis is known to be induced by mercury in cultured proximal tubular cells (15). In other models of acute renal failure, apoptosis occurs in two phases. The first phase occurs between 12 and 48 h after ischemic or nephrotoxic insult, which probably contributes to the tubular dysfunction associated with the acute renal failure. The second phase occurs later, during the recovery of acute renal failure, and contributes to the remodeling of the damaged tubules (31). Our studies did not extend to the repair stage of the nephrotoxic injury, but we were able to show that the pathogenic phase of apoptosis is improved by Mel.

Apoptosis may be induced by ROS (10), and by the generation of oxygenated derivatives of arachidonic acid, which are potent inducers of apoptosis (11). In addition, intracellular ROS generation results in the expression of genes responsible for apoptosis through the activation of nuclear transcription factors such as NF-κB (47). This process can also be inhibited by Mel (34).
To our knowledge, there are no previous studies of superoxide-producing cells in this experimental condition. Our findings show that the number of superoxide-positive proximal tubular cells increases ~20 times after 24 h of administration of HgCl₂. As shown in Figs. 7 and 8, Mel treatment reduced the number of superoxide-producing cells to normal (control) values. These results may be explained by the stimulation of superoxide dismutase by Mel (5) or by the superoxide scavenger properties of indolyl radicals resulting from -OH-induced oxidation of Mel (40).

The changes in the renal MDA, GSH content, and GSH-Px and catalase activities were more pronounced on the first day, with subsequent return toward control levels. As reported by others (1), we found that HgCl₂ induced a rapid increment in renal MDA content; lipid peroxidation was significantly reduced by Mel treatment (Fig. 6). HgCl₂ rapidly reacts with SH groups and depletes GSH in tubular cells, as evidenced by the early fall in GSH content of the kidney (Fig. 9). The Mel-treated group also had a significant early decrease in the renal content of GSH, although this effect was less pronounced than in the untreated group. Moreover, 48 h after the nephrotoxic insult, the GSH content in the Mel-treated group had returned to control levels. This rapid improvement may be partially due to increased GSH synthesis by Mel (1). HgCl₂-induced depletion of GSH is probably the cause for the early reduction in GSH-Px activity in this experimental model. GSH-Px activity was partially recovered by day 3, when the values in the HgCl₂-Mel group were not statistically significant in terms of control.

Mercury did not influence basal catalase activity, and this result is in agreement with the results of Nath et al. (36). Pretreatment with Mel produced an increment in catalase, as has been reported with other protective enzymes (5, 41).

The beneficial effects of Mel are only observed if the drug is given at least 30 min before the administration of HgCl₂. If Mel is given in conjunction with or after HgCl₂, the functional and histological damage are not prevented. In these circumstances, Mel treatment does not improve the changes in renal MDA, GSH, GSH-Px, and catalase resulting from mercury-induced ROS generation. Therefore, it appears that successful treatment of the intense oxidative stress generated in HgCl₂ nephrotoxicity requires preexisting availability of highly effective antioxidant mechanisms.

In summary, pretreatment with Mel, administered orally, markedly attenuates the acute nephrotoxicity produced by inorganic mercury. It is likely that the beneficial effects of the drug are related to its antioxidative action.

Part of this work was presented at the 31st Annual Meeting of the American Society of Nephrology and has appeared in abstract form (J Am Soc Nephrol 9: A2995, 1998).

REFERENCES


